Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Oligometastatic Prostate Cancer 1Mouth Neoplasms 1Melanoma 1Lung Diseases 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × zimberelimab × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06166589 2023-12-12

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
19 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡